Vita Therapeutics
801 W. Baltimore St. STE 301
Baltimore, MD 21201

April 22, 2024

Open Letter to the LGMD2A/R1 Community:

We are writing to provide an update on Vita Therapeutics, which is both exciting and also likely to cause some concern. In the previous 6 months Vita has achieved several important milestones and has made significant scientific progress. The highlights include a successful pre-IND meeting with the FDA for VTA-100, our autologous stem cell therapy for LGMD2A/R1, preclinical demonstration that VTA-200, our allogeneic hypoimmune therapy, can evade all aspects of the immune system, and we are developing a therapeutic approach to repair muscle systemically. We are excited to announce that we are moving forward with the development of our allogeneic approach to treating muscular dystrophy, which will result in a therapy which will universally treat all muscular dystrophies which result from a genetic loss of function etiology, including LGMD2A/R1, as well as a majority of LGMD subtypes and other types of muscular dystrophy such as FSHD, Beckers and Duchenne's Muscular Dystrophies. Given the great time and expense of manufacturing and development of both the autologous and allogeneic approaches, we have decided to proceed with the allogeneic pathway, a more universal therapeutic approach, which will mean that our first-in-human trial in LGMD2A/R1 will not be going forward in 2025 as originally planned.

This change of approach, which is ultimately very beneficial to the LGMD2A community, is a medically and commercially more viable approach, and was necessitated by a serious setback to our funding. Our financing to date has been committed through a series of investments and heading into the second half of 2023, $21 million was due from our investors. Our lead venture capital partner, Cambrian Biopharma, the investor who had $14 million outstanding, announced that they would be defaulting on their financial obligation due to current economic conditions. The remaining investors, comprising $7 million, chose not to fund as they felt the previously agreed upon terms from October of 2022 were no longer fair given this situation.

In light of these circumstances and with no immediate solutions, a new strategy was proposed for Vita's future. This strategy included pausing the development of our two autologous programs, including the program for VTA-100, continuing our systemic delivery R&D, and focusing on advancing VTA-200 (hypoimmunogenic satellite cells).

There is no denying that Vita's current financial situation has caused a significant setback that will result in further delays to our progress. However, given the data we've demonstrated to date and the scientific value we've created, we strongly believe that Vita still has a very bright future. We remain very committed to the LGMD2A/R1 community and are incredibly grateful for the support and effort that many have made on our behalf, including several who donated blood to assist in our product development. All of this effort has contributed to huge breakthroughs that will help us in developing VTA-200, which will ultimately be a better and more efficient therapy for calpainopathy. We thank you for your past support and we are excited to work every day towards a cure!

Vita Therapeutics
801 W. Baltimore St. STE 301
Baltimore, MD 21201

If you have any questions or concerns, please feel free to reach out to us at clinicaltrials@vita-therapeutics.com. We look forward to continuing our relationship with all of you.

Thank you.

Sincerely,

DocuSigned by:
Steven Brooks
059FBE373A77406...
Steven Brooks, SVP of Clinical Affairs

DocuSigned by:
Douglas Falk
31BF3F758969417...
Doug Falk, CEO